
Phenacetin−rat−HTPBTK−InVitro, RMSLE=0.439
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
23
250
360
factor(Route)
iv
oral


Phenacetin−human−HTPBTK−InVitro, RMSLE=0.439
Concentration (mg/L)
3
1
0.3
10^{-1}
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Dose)
3.38
13.5
factor(Route)
iv
oral


Phenacetin−rat−HTPBTK−ADMET, RMSLE=0.594
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
23
250
360
factor(Route)
iv
oral


Phenacetin−human−HTPBTK−ADMET, RMSLE=0.533
Concentration (mg/L)
3
1
0.3
10^{-1}
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Dose)
3.38
13.5
factor(Route)
iv
oral


Phenacetin−rat−HTPBTK−Dawson, RMSLE=0.473
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
23
250
360
factor(Route)
iv
oral


Phenacetin−human−HTPBTK−Dawson, RMSLE=0.45
Concentration (mg/L)
3
1
0.3
10^{-1}
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Dose)
3.38
13.5
factor(Route)
iv
oral


Phenacetin−rat−HTPBTK−Pradeep, RMSLE=0.406
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
23
250
360
factor(Route)
iv
oral


Phenacetin−human−HTPBTK−Pradeep, RMSLE=0.412
Concentration (mg/L)
3
1
0.3
10^{-1}
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Dose)
3.38
13.5
factor(Route)
iv
oral


Phenacetin−rat−HTPBTK−Consensus, RMSLE=0.413
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
23
250
360
factor(Route)
iv
oral


Phenacetin−human−HTPBTK−Consensus, RMSLE=0.411
Concentration (mg/L)
3
1
0.3
10^{-1}
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Dose)
3.38
13.5
factor(Route)
iv
oral


Phenacetin−human−In Vivo Fits, RMSLE=0.41
Concentration (mg/L)
3
1
0.3
10^{-1}
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Dose)
3.38
13.5
factor(Route)
iv
oral


Dichloromethane−rat−HTPBTK−InVitro, RMSLE=0.708
Concentration (mg/L)
10^2
30
10
3
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Route)
oral
factor(Dose)
125


Dichloromethane−rat−HTPBTK−Consensus, RMSLE=1.17
Concentration (mg/L)
10^2
30
10
3
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Route)
oral
factor(Dose)
125


1,2−Dichloroethane−rat−HTPBTK−InVitro, RMSLE=0.626
Concentration (mg/L)
30
10
3
1
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Route)
oral
factor(Dose)
100


1,2−Dichloroethane−rat−HTPBTK−Consensus, RMSLE=1.08
Concentration (mg/L)
30
10
3
1
0.00
0.05
0.10
0.15
0.20
Time (Days)
factor(Route)
oral
factor(Dose)
100


Trichloroethylene−rat−HTPBTK−InVitro, RMSLE=0.76
Concentration (mg/L)
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
oral
factor(Dose)
7.6
18


Trichloroethylene−rat−HTPBTK−Consensus, RMSLE=1.66
Concentration (mg/L)
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
oral
factor(Dose)
7.6
18


1,4−Dioxane−rat−HTPBTK−InVitro, RMSLE=1.82
Concentration (mg/L)
10^3
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
3
10
30
100
300
1000
factor(Route)
iv


1,4−Dioxane−rat−HTPBTK−Consensus, RMSLE=1.96
Concentration (mg/L)
10^3
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
3
10
30
100
300
1000
factor(Route)
iv


1,4−Dioxane−rat−In Vivo Fits, RMSLE=0.545
Concentration (mg/L)
10^3
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
3
10
30
100
300
1000
factor(Route)
iv


Benzo[a]pyrene−rat−HTPBTK−InVitro, RMSLE=0.678
Concentration (mg/L)
10
10^{-1}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.0556
2
6
10.1
15
factor(Route)
iv


Benzo[a]pyrene−rat−HTPBTK−ADMET, RMSLE=0.678
Concentration (mg/L)
10
10^{-1}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.0556
2
6
10.1
15
factor(Route)
iv


Benzo[a]pyrene−rat−HTPBTK−Dawson, RMSLE=0.677
Concentration (mg/L)
10
10^{-1}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.0556
2
6
10.1
15
factor(Route)
iv


Benzo[a]pyrene−rat−HTPBTK−OPERA, RMSLE=0.677
Concentration (mg/L)
10
10^{-1}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.0556
2
6
10.1
15
factor(Route)
iv


Benzo[a]pyrene−rat−HTPBTK−Consensus, RMSLE=0.678
Concentration (mg/L)
10
10^{-1}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.0556
2
6
10.1
15
factor(Route)
iv


Benzo[a]pyrene−rat−In Vivo Fits, RMSLE=0.863
Concentration (mg/L)
10
10^{-1}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.0556
2
6
10.1
15
factor(Route)
iv


Acrylonitrile−rat−HTPBTK−InVitro, RMSLE=0.459
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.01
0.02
0.03
0.04
0.05
Time (Days)
factor(Dose)
3.4
47
55
84
factor(Route)
iv


Acrylonitrile−rat−HTPBTK−Consensus, RMSLE=0.328
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.01
0.02
0.03
0.04
0.05
Time (Days)
factor(Dose)
3.4
47
55
84
factor(Route)
iv


Acrylonitrile−rat−In Vivo Fits, RMSLE=0.217
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.01
0.02
0.03
0.04
0.05
Time (Days)
factor(Dose)
3.4
47
55
84
factor(Route)
iv


2,4−Dichlorophenoxyacetic acid−rat−HTPBTK−InVitro, RMSLE=0.762
Concentration (mg/L)
10
10^{-1}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
0.205
1.04
1.5
2
3.56
7
factor(Route)
iv
oral


2,4−Dichlorophenoxyacetic acid−rat−HTPBTK−ADMET, RMSLE=1.13
Concentration (mg/L)
10
10^{-1}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
0.205
1.04
1.5
2
3.56
7
factor(Route)
iv
oral


2,4−Dichlorophenoxyacetic acid−rat−HTPBTK−Pradeep, RMSLE=1.15
Concentration (mg/L)
10
10^{-1}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
0.205
1.04
1.5
2
3.56
7
factor(Route)
iv
oral


2,4−Dichlorophenoxyacetic acid−rat−HTPBTK−Consensus, RMSLE=1.57
Concentration (mg/L)
10
10^{-1}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
0.205
1.04
1.5
2
3.56
7
factor(Route)
iv
oral


2,4−Dichlorophenoxyacetic acid−rat−In Vivo Fits, RMSLE=0.403
Concentration (mg/L)
10
10^{-1}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
0.205
1.04
1.5
2
3.56
7
factor(Route)
iv
oral


Alachlor−rat−HTPBTK−InVitro, RMSLE=1.68
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5.2
factor(Route)
iv
oral


Alachlor−rat−HTPBTK−ADMET, RMSLE=1.79
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5.2
factor(Route)
iv
oral


Alachlor−rat−HTPBTK−Dawson, RMSLE=1.92
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5.2
factor(Route)
iv
oral


Alachlor−rat−HTPBTK−Pradeep, RMSLE=1.95
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5.2
factor(Route)
iv
oral


Alachlor−rat−HTPBTK−Consensus, RMSLE=1.68
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5.2
factor(Route)
iv
oral


Alachlor−rat−In Vivo Fits, RMSLE=0.463
Concentration (mg/L)
10^{-2}
10^{-3}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5.2
factor(Route)
iv
oral


Alprazolam−rat−HTPBTK−InVitro, RMSLE=1.75
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
0.20
0.25
Time (Days)
factor(Dose)
1.25
7
12.5
factor(Route)
iv
oral


Alprazolam−rat−HTPBTK−ADMET, RMSLE=0.992
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
0.20
0.25
Time (Days)
factor(Dose)
1.25
7
12.5
factor(Route)
iv
oral


Alprazolam−rat−HTPBTK−Dawson, RMSLE=1.01
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
0.20
0.25
Time (Days)
factor(Dose)
1.25
7
12.5
factor(Route)
iv
oral


Alprazolam−rat−HTPBTK−Pradeep, RMSLE=1
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
0.20
0.25
Time (Days)
factor(Dose)
1.25
7
12.5
factor(Route)
iv
oral


Alprazolam−rat−HTPBTK−Consensus, RMSLE=0.729
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
0.20
0.25
Time (Days)
factor(Dose)
1.25
7
12.5
factor(Route)
iv
oral


Alprazolam−rat−In Vivo Fits, RMSLE=0.234
1
10^{-1}
10^{-2}
Concentration (mg/L)
0.00
0.05
0.10
0.15
0.20
0.25
Time (Days)
factor(Dose)
1.25
7
12.5
factor(Route)
iv
oral


Bensulide−rat−HTPBTK−InVitro, RMSLE=0.738
Concentration (mg/L)
1
10^{-2}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5
5.18
factor(Route)
iv
oral


Bensulide−rat−HTPBTK−ADMET, RMSLE=0.7
Concentration (mg/L)
1
10^{-2}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5
5.18
factor(Route)
iv
oral


Bensulide−rat−HTPBTK−Dawson, RMSLE=0.968
Concentration (mg/L)
1
10^{-2}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5
5.18
factor(Route)
iv
oral


Bensulide−rat−HTPBTK−Pradeep, RMSLE=1.15
Concentration (mg/L)
1
10^{-2}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5
5.18
factor(Route)
iv
oral


Bensulide−rat−HTPBTK−Consensus, RMSLE=0.656
Concentration (mg/L)
1
10^{-2}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5
5.18
factor(Route)
iv
oral


Bensulide−rat−In Vivo Fits, RMSLE=0.402
Concentration (mg/L)
1
10^{-2}
10^{-4}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
5
5.18
factor(Route)
iv
oral


Bisphenol A−rat−HTPBTK−InVitro, RMSLE=0.464
Concentration (mg/L)
0.3
10^{-1}
0.03
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
0.6
factor(Route)
iv


Bisphenol A−rat−HTPBTK−ADMET, RMSLE=0.615
Concentration (mg/L)
0.3
10^{-1}
0.03
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
0.6
factor(Route)
iv


Bisphenol A−rat−HTPBTK−Dawson, RMSLE=0.464
Concentration (mg/L)
0.3
10^{-1}
0.03
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
0.6
factor(Route)
iv


Bisphenol A−rat−HTPBTK−Pradeep, RMSLE=0.45
Concentration (mg/L)
0.3
10^{-1}
0.03
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
0.6
factor(Route)
iv


Bisphenol A−rat−HTPBTK−Consensus, RMSLE=0.451
Concentration (mg/L)
0.3
10^{-1}
0.03
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
0.6
factor(Route)
iv


Bisphenol A−rat−In Vivo Fits, RMSLE=0.091
Concentration (mg/L)
0.3
10^{-1}
0.03
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
0.6
factor(Route)
iv


Boscalid−rat−HTPBTK−InVitro, RMSLE=0.614
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Boscalid−rat−HTPBTK−ADMET, RMSLE=0.756
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Boscalid−rat−HTPBTK−Dawson, RMSLE=0.563
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Boscalid−rat−HTPBTK−Pradeep, RMSLE=0.66
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Boscalid−rat−HTPBTK−Consensus, RMSLE=0.565
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Boscalid−rat−In Vivo Fits, RMSLE=0.196
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Bosentan−rat−HTPBTK−InVitro, RMSLE=0.261
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
1
10
factor(Route)
iv
oral


Bosentan−rat−HTPBTK−ADMET, RMSLE=0.779
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
1
10
factor(Route)
iv
oral


Bosentan−rat−HTPBTK−Dawson, RMSLE=0.609
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
1
10
factor(Route)
iv
oral


Bosentan−rat−HTPBTK−Pradeep, RMSLE=0.29
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
1
10
factor(Route)
iv
oral


Bosentan−rat−HTPBTK−Consensus, RMSLE=0.76
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
1
10
factor(Route)
iv
oral


Bosentan−rat−In Vivo Fits, RMSLE=0.0448
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
1
10
factor(Route)
iv
oral


1−Naphthalenol, 1−(N−methylcarbamate)−rat−HTPBTK−InVitro, RMSLE=1.82
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


1−Naphthalenol, 1−(N−methylcarbamate)−rat−HTPBTK−ADMET, RMSLE=1.58
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


1−Naphthalenol, 1−(N−methylcarbamate)−rat−HTPBTK−Dawson, RMSLE=1.89
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


1−Naphthalenol, 1−(N−methylcarbamate)−rat−HTPBTK−Pradeep, RMSLE=1.89
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


1−Naphthalenol, 1−(N−methylcarbamate)−rat−HTPBTK−Consensus, RMSLE=1.5
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


1−Naphthalenol, 1−(N−methylcarbamate)−rat−In Vivo Fits, RMSLE=0.137
Concentration (mg/L)
10^{-2}
0.003
10^{-3}
0.01
0.02
0.03
0.04
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Carbendazim−rat−HTPBTK−InVitro, RMSLE=1.06
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
0.8
Time (Days)
factor(Route)
oral
factor(Dose)
1000


Carbendazim−rat−HTPBTK−ADMET, RMSLE=1.12
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
0.8
Time (Days)
factor(Route)
oral
factor(Dose)
1000


Carbendazim−rat−HTPBTK−Dawson, RMSLE=1.09
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
0.8
Time (Days)
factor(Route)
oral
factor(Dose)
1000


Carbendazim−rat−HTPBTK−Pradeep, RMSLE=1.09
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
0.8
Time (Days)
factor(Route)
oral
factor(Dose)
1000


Carbendazim−rat−HTPBTK−Consensus, RMSLE=1.1
Concentration (mg/L)
10
1
10^{-1}
0.0
0.2
0.4
0.6
0.8
Time (Days)
factor(Route)
oral
factor(Dose)
1000


Chloridazon−rat−HTPBTK−InVitro, RMSLE=0.8
Concentration (mg/L)
1
10^{-2}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.8
4.17
factor(Route)
iv
oral


Chloridazon−rat−HTPBTK−ADMET, RMSLE=0.869
Concentration (mg/L)
1
10^{-2}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.8
4.17
factor(Route)
iv
oral


Chloridazon−rat−HTPBTK−Dawson, RMSLE=1.14
Concentration (mg/L)
1
10^{-2}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.8
4.17
factor(Route)
iv
oral


Chloridazon−rat−HTPBTK−Pradeep, RMSLE=1.07
Concentration (mg/L)
1
10^{-2}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.8
4.17
factor(Route)
iv
oral


Chloridazon−rat−HTPBTK−Consensus, RMSLE=1.25
Concentration (mg/L)
1
10^{-2}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.8
4.17
factor(Route)
iv
oral


Chloridazon−rat−In Vivo Fits, RMSLE=0.684
Concentration (mg/L)
1
10^{-2}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.8
4.17
factor(Route)
iv
oral


Chlorpyrifos−rat−HTPBTK−InVitro, RMSLE=1.74
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
10
50
100
factor(Route)
oral


Chlorpyrifos−rat−HTPBTK−ADMET, RMSLE=1.49
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
10
50
100
factor(Route)
oral


Chlorpyrifos−rat−HTPBTK−Dawson, RMSLE=1.52
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
10
50
100
factor(Route)
oral


Chlorpyrifos−rat−HTPBTK−Pradeep, RMSLE=1.58
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
10
50
100
factor(Route)
oral


Chlorpyrifos−rat−HTPBTK−Consensus, RMSLE=1.47
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
10
50
100
factor(Route)
oral


Cyclanilide−rat−HTPBTK−InVitro, RMSLE=0.676
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.2
1
factor(Route)
iv
oral


Cyclanilide−rat−HTPBTK−ADMET, RMSLE=1.2
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.2
1
factor(Route)
iv
oral


Cyclanilide−rat−HTPBTK−Dawson, RMSLE=1.51
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.2
1
factor(Route)
iv
oral


Cyclanilide−rat−HTPBTK−Pradeep, RMSLE=1.57
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.2
1
factor(Route)
iv
oral


Cyclanilide−rat−HTPBTK−Consensus, RMSLE=1.87
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.2
1
factor(Route)
iv
oral


Cyclanilide−rat−In Vivo Fits, RMSLE=0.232
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
0.2
1
factor(Route)
iv
oral


Diazoxon−rat−HTPBTK−InVitro, RMSLE=1.67
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1.02
5.02


Diazoxon−rat−HTPBTK−ADMET, RMSLE=2.08
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1.02
5.02


Diazoxon−rat−HTPBTK−Dawson, RMSLE=1.61
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1.02
5.02


Diazoxon−rat−HTPBTK−Pradeep, RMSLE=1.59
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1.02
5.02


Diazoxon−rat−HTPBTK−Consensus, RMSLE=1.92
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1.02
5.02


Diazoxon−rat−In Vivo Fits, RMSLE=0.524
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1.02
5.02


Dimethenamid−rat−HTPBTK−InVitro, RMSLE=1.51
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Dimethenamid−rat−HTPBTK−ADMET, RMSLE=1.31
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Dimethenamid−rat−HTPBTK−Dawson, RMSLE=1.49
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Dimethenamid−rat−HTPBTK−Pradeep, RMSLE=1.63
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Dimethenamid−rat−HTPBTK−Consensus, RMSLE=1.18
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Dimethenamid−rat−In Vivo Fits, RMSLE=0.475
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Fenarimol−rat−HTPBTK−InVitro, RMSLE=0.767
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.003
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Fenarimol−rat−HTPBTK−ADMET, RMSLE=0.491
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Fenarimol−rat−HTPBTK−Dawson, RMSLE=0.52
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Fenarimol−rat−HTPBTK−Consensus, RMSLE=0.492
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Fenarimol−rat−In Vivo Fits, RMSLE=0.24
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Formetanate hydrochloride−rat−HTPBTK−InVitro, RMSLE=0.814
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.003
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Formetanate hydrochloride−rat−HTPBTK−ADMET, RMSLE=0.538
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Formetanate hydrochloride−rat−HTPBTK−Dawson, RMSLE=0.931
1
10^{-1}
10^{-2}
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Formetanate hydrochloride−rat−HTPBTK−Pradeep, RMSLE=0.878
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Formetanate hydrochloride−rat−HTPBTK−Consensus, RMSLE=0.563
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Formetanate hydrochloride−rat−In Vivo Fits, RMSLE=0.346
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Ibuprofen−rat−HTPBTK−InVitro, RMSLE=1.25
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
2.5
25
factor(Route)
iv


Ibuprofen−rat−HTPBTK−ADMET, RMSLE=0.902
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
2.5
25
factor(Route)
iv


Ibuprofen−rat−HTPBTK−Dawson, RMSLE=1.3
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
2.5
25
factor(Route)
iv


Ibuprofen−rat−HTPBTK−Pradeep, RMSLE=1.15
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
2.5
25
factor(Route)
iv


Ibuprofen−rat−HTPBTK−Consensus, RMSLE=1.31
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
2.5
25
factor(Route)
iv


Ibuprofen−rat−In Vivo Fits, RMSLE=0.161
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
2.5
25
factor(Route)
iv


Imazalil−rat−HTPBTK−InVitro, RMSLE=1.5
1
10^{-1}
10^{-2}
10^{-3}
Concentration (mg/L)
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Imazalil−rat−HTPBTK−ADMET, RMSLE=1.11
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Imazalil−rat−HTPBTK−Dawson, RMSLE=0.875
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Imazalil−rat−HTPBTK−Pradeep, RMSLE=1.37
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Imazalil−rat−HTPBTK−Consensus, RMSLE=0.758
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Imazalil−rat−In Vivo Fits, RMSLE=0.121
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Imidacloprid−rat−HTPBTK−InVitro, RMSLE=1.25
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
5
factor(Route)
iv
oral


Imidacloprid−rat−HTPBTK−ADMET, RMSLE=1.16
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
5
factor(Route)
iv
oral


Imidacloprid−rat−HTPBTK−Dawson, RMSLE=1.42
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
5
factor(Route)
iv
oral


Imidacloprid−rat−HTPBTK−Pradeep, RMSLE=1.35
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
5
factor(Route)
iv
oral


Imidacloprid−rat−HTPBTK−Consensus, RMSLE=1.41
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
5
factor(Route)
iv
oral


Imidacloprid−rat−In Vivo Fits, RMSLE=0.423
Concentration (mg/L)
1
10^{-1}
10^{-2}
0
1
2
3
Time (Days)
factor(Dose)
5
factor(Route)
iv
oral


Imipramine−rat−HTPBTK−InVitro, RMSLE=0.332
Concentration (mg/L)
3
1
0.3
10^{-1}
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
50
factor(Route)
iv
oral


Imipramine−rat−HTPBTK−ADMET, RMSLE=0.599
Concentration (mg/L)
3
1
0.3
10−1
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
50
factor(Route)
iv
oral


Imipramine−rat−HTPBTK−Dawson, RMSLE=0.428
Concentration (mg/L)
3
1
0.3
10−1
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
50
factor(Route)
iv
oral


Imipramine−rat−HTPBTK−Pradeep, RMSLE=0.927
Concentration (mg/L)
3
1
0.3
10^{-1}
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
50
factor(Route)
iv
oral


Imipramine−rat−HTPBTK−Consensus, RMSLE=0.333
Concentration (mg/L)
3
1
0.3
10−1
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
50
factor(Route)
iv
oral


Imipramine−rat−In Vivo Fits, RMSLE=0.129
Concentration (mg/L)
1
0.3
10^{-1}
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
10
50
factor(Route)
iv
oral


Midazolam−rat−HTPBTK−InVitro, RMSLE=0.957
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
5
15
factor(Route)
iv
oral


Midazolam−rat−HTPBTK−Dawson, RMSLE=1.21
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
5
15
factor(Route)
iv
oral


Midazolam−rat−HTPBTK−Consensus, RMSLE=0.44
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
5
15
factor(Route)
iv
oral


Midazolam−rat−In Vivo Fits, RMSLE=0.142
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
5
15
factor(Route)
iv
oral


Nilvadipine−rat−HTPBTK−InVitro, RMSLE=1.06
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Nilvadipine−rat−HTPBTK−ADMET, RMSLE=0.845
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Nilvadipine−rat−HTPBTK−Dawson, RMSLE=0.984
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Nilvadipine−rat−HTPBTK−Pradeep, RMSLE=0.937
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Nilvadipine−rat−HTPBTK−OPERA, RMSLE=0.929
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Nilvadipine−rat−HTPBTK−Consensus, RMSLE=1.03
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Nilvadipine−rat−In Vivo Fits, RMSLE=0.331
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
0.1
10
factor(Route)
iv
oral


Ondansetron−rat−HTPBTK−InVitro, RMSLE=1
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1
4
8
20


Ondansetron−rat−HTPBTK−ADMET, RMSLE=0.685
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1
4
8
20


Ondansetron−rat−HTPBTK−Dawson, RMSLE=0.604
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1
4
8
20


Ondansetron−rat−HTPBTK−Pradeep, RMSLE=0.965
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1
4
8
20


Ondansetron−rat−HTPBTK−Consensus, RMSLE=0.609
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1
4
8
20


Ondansetron−rat−In Vivo Fits, RMSLE=0.146
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.05
0.10
0.15
Time (Days)
factor(Route)
iv
oral
factor(Dose)
1
4
8
20


Perfluorooctanoic acid−rat−HTPBTK−InVitro, RMSLE=2.16
Concentration (mg/L)
10^2
10
1
10^{-1}
0
10
20
30
40
50
Time (Days)
factor(Dose)
0.2
1
6
12
40
48
80
320
factor(Route)
iv
oral


Perfluorooctanoic acid−rat−HTPBTK−Consensus, RMSLE=2.18
Concentration (mg/L)
10^2
10
1
10^{-1}
0
10
20
30
40
50
Time (Days)
factor(Dose)
0.2
1
6
12
40
48
80
320
factor(Route)
iv
oral


Perfluorooctanoic acid−rat−In Vivo Fits, RMSLE=0.681
Concentration (mg/L)
10^3
10^2
10
1
10^{-1}
0
10
20
30
40
50
Time (Days)
factor(Dose)
0.2
1
6
12
40
48
80
320
factor(Route)
iv
oral


Permethrin−rat−HTPBTK−InVitro, RMSLE=1.15
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Permethrin−rat−HTPBTK−ADMET, RMSLE=1.11
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Permethrin−rat−HTPBTK−Dawson, RMSLE=0.916
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Permethrin−rat−HTPBTK−Consensus, RMSLE=1.17
Concentration (mg/L)
10^{-1}
0.03
10^{-2}
0.003
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Permethrin−rat−In Vivo Fits, RMSLE=0.29
Concentration (mg/L)
10^−1
0.03
10^−2
0.003
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


5,5−Diphenylhydantoin−rat−HTPBTK−InVitro, RMSLE=0.551
Concentration (mg/L)
10^2
10
1
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
40
factor(Route)
iv
oral


5,5−Diphenylhydantoin−rat−HTPBTK−ADMET, RMSLE=0.617
Concentration (mg/L)
10^2
10
1
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
40
factor(Route)
iv
oral


5,5−Diphenylhydantoin−rat−HTPBTK−Dawson, RMSLE=0.552
Concentration (mg/L)
10^2
10
1
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
40
factor(Route)
iv
oral


5,5−Diphenylhydantoin−rat−HTPBTK−Pradeep, RMSLE=0.357
Concentration (mg/L)
10^2
10
1
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
40
factor(Route)
iv
oral


5,5−Diphenylhydantoin−rat−HTPBTK−Consensus, RMSLE=0.552
Concentration (mg/L)
10^2
10
1
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
40
factor(Route)
iv
oral


5,5−Diphenylhydantoin−rat−In Vivo Fits, RMSLE=0.258
Concentration (mg/L)
10^2
10
1
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
40
factor(Route)
iv
oral


Propamocarb hydrochloride−rat−HTPBTK−InVitro, RMSLE=2.2
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.02
0.04
0.06
0.08
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Propamocarb hydrochloride−rat−HTPBTK−ADMET, RMSLE=1.93
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.02
0.04
0.06
0.08
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Propamocarb hydrochloride−rat−HTPBTK−Dawson, RMSLE=2.42
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.02
0.04
0.06
0.08
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Propamocarb hydrochloride−rat−HTPBTK−Consensus, RMSLE=1.94
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.02
0.04
0.06
0.08
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Propamocarb hydrochloride−rat−In Vivo Fits, RMSLE=0.253
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0.00
0.02
0.04
0.06
0.08
Time (Days)
factor(Dose)
1
5
factor(Route)
iv
oral


Propyzamide−rat−HTPBTK−InVitro, RMSLE=0.744
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.6
0.608
3
3.21


Propyzamide−rat−HTPBTK−ADMET, RMSLE=1
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.6
0.608
3
3.21


Propyzamide−rat−HTPBTK−Dawson, RMSLE=1.09
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.6
0.608
3
3.21


Propyzamide−rat−HTPBTK−Consensus, RMSLE=1.05
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.6
0.608
3
3.21


Propyzamide−rat−In Vivo Fits, RMSLE=0.391
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.6
0.608
3
3.21


Pyrithiobac sodium−rat−HTPBTK−InVitro, RMSLE=1.49
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.203
1.04
factor(Route)
iv
oral


Pyrithiobac sodium−rat−HTPBTK−ADMET, RMSLE=1.37
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.203
1.04
factor(Route)
iv
oral


Pyrithiobac sodium−rat−HTPBTK−Dawson, RMSLE=1.36
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.203
1.04
factor(Route)
iv
oral


Pyrithiobac sodium−rat−HTPBTK−Pradeep, RMSLE=1.57
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.203
1.04
factor(Route)
iv
oral


Pyrithiobac sodium−rat−HTPBTK−Consensus, RMSLE=1.64
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.203
1.04
factor(Route)
iv
oral


Pyrithiobac sodium−rat−In Vivo Fits, RMSLE=0.18
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.203
1.04
factor(Route)
iv
oral


S−Bioallethrin−rat−HTPBTK−InVitro, RMSLE=0.869
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


S−Bioallethrin−rat−HTPBTK−ADMET, RMSLE=0.914
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


S−Bioallethrin−rat−HTPBTK−Dawson, RMSLE=0.981
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


S−Bioallethrin−rat−HTPBTK−OPERA, RMSLE=1.08
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


S−Bioallethrin−rat−HTPBTK−Consensus, RMSLE=0.798
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


S−Bioallethrin−rat−In Vivo Fits, RMSLE=0.253
Concentration (mg/L)
0.03
10^{-2}
0.003
10^{-3}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


Simazine−rat−HTPBTK−InVitro, RMSLE=1.38
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Simazine−rat−HTPBTK−ADMET, RMSLE=1.07
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Simazine−rat−HTPBTK−Consensus, RMSLE=0.962
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Simazine−rat−In Vivo Fits, RMSLE=0.326
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Tolbutamide−rat−HTPBTK−InVitro, RMSLE=0.438
Concentration (mg/L)
50
30
20
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
20
factor(Route)
iv
oral


Tolbutamide−rat−HTPBTK−ADMET, RMSLE=0.465
Concentration (mg/L)
50
30
20
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
20
factor(Route)
iv
oral


Tolbutamide−rat−HTPBTK−Dawson, RMSLE=0.465
Concentration (mg/L)
50
30
20
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
20
factor(Route)
iv
oral


Tolbutamide−rat−HTPBTK−Pradeep, RMSLE=0.465
Concentration (mg/L)
50
30
20
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
20
factor(Route)
iv
oral


Tolbutamide−rat−HTPBTK−Consensus, RMSLE=0.465
Concentration (mg/L)
50
30
20
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
20
factor(Route)
iv
oral


Tolbutamide−rat−In Vivo Fits, RMSLE=0.0706
10^2
50
30
Concentration (mg/L)
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
20
factor(Route)
iv
oral


Triclosan−rat−HTPBTK−InVitro, RMSLE=0.952
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
factor(Route)
iv


Triclosan−rat−HTPBTK−ADMET, RMSLE=0.952
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
factor(Route)
iv


Triclosan−rat−HTPBTK−Dawson, RMSLE=0.948
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
factor(Route)
iv


Triclosan−rat−HTPBTK−Pradeep, RMSLE=0.948
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
factor(Route)
iv


Triclosan−rat−HTPBTK−Consensus, RMSLE=0.988
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
factor(Route)
iv


Triclosan−rat−In Vivo Fits, RMSLE=0.712
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0
1
2
3
Time (Days)
factor(Dose)
1
factor(Route)
iv


Valproic acid−rat−HTPBTK−InVitro, RMSLE=0.459
Concentration (mg/L)
10^3
10^2
10
1
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
10
50
100
200
600
factor(Route)
iv
oral


Valproic acid−rat−HTPBTK−Dawson, RMSLE=0.615
Concentration (mg/L)
10^3
10^2
10
1
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
10
50
100
200
600
factor(Route)
iv
oral


Valproic acid−rat−HTPBTK−Pradeep, RMSLE=1.16
Concentration (mg/L)
10^3
10^2
10
1
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
10
50
100
200
600
factor(Route)
iv
oral


Valproic acid−rat−HTPBTK−OPERA, RMSLE=0.504
Concentration (mg/L)
10^3
10^2
10
1
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
10
50
100
200
600
factor(Route)
iv
oral


Valproic acid−rat−HTPBTK−Consensus, RMSLE=1.38
Concentration (mg/L)
10^3
10^2
10
1
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
10
50
100
200
600
factor(Route)
iv
oral


Valproic acid−rat−In Vivo Fits, RMSLE=0.151
Concentration (mg/L)
10^3
10^2
10
1
0.00
0.05
0.10
0.15
Time (Days)
factor(Dose)
10
50
100
200
600
factor(Route)
iv
oral


Potassium perfluorohexanesulfonate−rat−HTPBTK−InVitro, RMSLE=0.724
Concentration (mg/L)
10^2
10
1
10^{-1}
0
10
20
30
40
50
Time (Days)
factor(Dose)
4
16
32
factor(Route)
iv
oral


Potassium perfluorohexanesulfonate−rat−HTPBTK−Consensus, RMSLE=0.842
Concentration (mg/L)
10^2
10
1
10^{-1}
0
10
20
30
40
50
Time (Days)
factor(Dose)
4
16
32
factor(Route)
iv
oral


Potassium perfluorohexanesulfonate−rat−In Vivo Fits, RMSLE=0.621
Concentration (mg/L)
10^2
10
1
10^{-1}
0
10
20
30
40
50
Time (Days)
factor(Dose)
4
16
32
factor(Route)
iv
oral


Potassium perfluorobutanesulfonate−rat−HTPBTK−InVitro, RMSLE=1.19
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
4
20
100
factor(Route)
iv
oral


Potassium perfluorobutanesulfonate−rat−HTPBTK−Consensus, RMSLE=1.19
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
4
20
100
factor(Route)
iv
oral


Potassium perfluorobutanesulfonate−rat−In Vivo Fits, RMSLE=0.496
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
4
20
100
factor(Route)
iv
oral


Perfluorohexanoic acid−rat−HTPBTK−InVitro, RMSLE=1.48
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
40
80
160
factor(Route)
iv
oral


Perfluorohexanoic acid−rat−HTPBTK−Consensus, RMSLE=1.47
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
40
80
160
factor(Route)
iv
oral


Perfluorohexanoic acid−rat−In Vivo Fits, RMSLE=0.622
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
40
80
160
factor(Route)
iv
oral


Perfluorodecanoic acid−rat−HTPBTK−InVitro, RMSLE=1.01
Concentration (mg/L)
10^2
10
1
10^{-1}
0
50
100
Time (Days)
factor(Dose)
2
10
20
factor(Route)
iv
oral


Perfluorodecanoic acid−rat−HTPBTK−Consensus, RMSLE=0.486
Concentration (mg/L)
10^2
10
1
10^{-1}
0
50
100
Time (Days)
factor(Dose)
2
10
20
factor(Route)
iv
oral


Perfluorodecanoic acid−rat−In Vivo Fits, RMSLE=0.173
Concentration (mg/L)
10^2
10
1
10^{-1}
0
50
100
Time (Days)
factor(Dose)
2
10
20
factor(Route)
iv
oral


Methyleugenol−rat−HTPBTK−InVitro, RMSLE=0.836
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
37
75
150
factor(Route)
iv
oral


Methyleugenol−rat−HTPBTK−Consensus, RMSLE=0.823
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
37
75
150
factor(Route)
iv
oral


Oxazepam−rat−HTPBTK−InVitro, RMSLE=0.912
Concentration (mg/L)
10^2
10
1
0.0
0.3
0.6
0.9
Time (Days)
factor(Dose)
20
50
200
400
factor(Route)
iv
oral


Oxazepam−rat−HTPBTK−ADMET, RMSLE=0.837
Concentration (mg/L)
10^2
10
1
0.0
0.3
0.6
0.9
Time (Days)
factor(Dose)
20
50
200
400
factor(Route)
iv
oral


Oxazepam−rat−HTPBTK−Dawson, RMSLE=0.836
Concentration (mg/L)
10^2
10
1
0.0
0.3
0.6
0.9
Time (Days)
factor(Dose)
20
50
200
400
factor(Route)
iv
oral


Oxazepam−rat−HTPBTK−Pradeep, RMSLE=0.872
Concentration (mg/L)
10^2
10
1
0.0
0.3
0.6
0.9
Time (Days)
factor(Dose)
20
50
200
400
factor(Route)
iv
oral


Oxazepam−rat−HTPBTK−Consensus, RMSLE=0.774
Concentration (mg/L)
30
10
3
1
0.3
0.0
0.3
0.6
0.9
Time (Days)
factor(Dose)
20
50
200
400
factor(Route)
iv
oral


Oxazepam−rat−In Vivo Fits, RMSLE=0.234
Concentration (mg/L)
10
3
1
0.3
0.0
0.3
0.6
0.9
Time (Days)
factor(Dose)
20
50
200
400
factor(Route)
iv
oral


Pentachlorophenol−rat−HTPBTK−InVitro, RMSLE=1.42
Concentration (mg/L)
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
5
9.5
18.8
38
75
150
factor(Route)
iv
oral


Pentachlorophenol−rat−HTPBTK−ADMET, RMSLE=0.725
Concentration (mg/L)
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
5
9.5
18.8
38
75
150
factor(Route)
iv
oral


Pentachlorophenol−rat−HTPBTK−Pradeep, RMSLE=1.44
Concentration (mg/L)
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
5
9.5
18.8
38
75
150
factor(Route)
iv
oral


Pentachlorophenol−rat−HTPBTK−Consensus, RMSLE=1.48
Concentration (mg/L)
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
5
9.5
18.8
38
75
150
factor(Route)
iv
oral


Pentachlorophenol−rat−In Vivo Fits, RMSLE=0.293
Concentration (mg/L)
10^2
10
1
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
5
9.5
18.8
38
75
150
factor(Route)
iv
oral


Gemfibrozil−rat−HTPBTK−InVitro, RMSLE=1.11
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
4.29
50
100
factor(Route)
iv
oral


Gemfibrozil−rat−HTPBTK−ADMET, RMSLE=0.98
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
4.29
50
100
factor(Route)
iv
oral


Gemfibrozil−rat−HTPBTK−Dawson, RMSLE=1.02
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
4.29
50
100
factor(Route)
iv
oral


Gemfibrozil−rat−HTPBTK−Pradeep, RMSLE=1.01
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
4.29
50
100
factor(Route)
iv
oral


Gemfibrozil−rat−HTPBTK−Consensus, RMSLE=1.11
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
4.29
50
100
factor(Route)
iv
oral


Gemfibrozil−rat−In Vivo Fits, RMSLE=0.335
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
4.29
50
100
factor(Route)
iv
oral


Dibutyl 1,2−benzenedicarboxylate−rat−HTPBTK−InVitro, RMSLE=0.388
Concentration (mg/L)
10
3
1
0.003
0.006
0.009
0.012
Time (Days)
factor(Dose)
20
factor(Route)
iv


Dibutyl 1,2−benzenedicarboxylate−rat−HTPBTK−Dawson, RMSLE=0.395
Concentration (mg/L)
10
3
1
0.003
0.006
0.009
0.012
Time (Days)
factor(Dose)
20
factor(Route)
iv


Dibutyl 1,2−benzenedicarboxylate−rat−HTPBTK−Consensus, RMSLE=0.385
Concentration (mg/L)
10
3
1
0.003
0.006
0.009
0.012
Time (Days)
factor(Dose)
20
factor(Route)
iv


Dibutyl 1,2−benzenedicarboxylate−rat−In Vivo Fits, RMSLE=0.29
10
3
1
Concentration (mg/L)
0.003
0.006
0.009
0.012
Time (Days)
factor(Dose)
20
factor(Route)
iv


Naphthalene−rat−HTPBTK−InVitro, RMSLE=0.437
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
3
10
factor(Route)
iv


Naphthalene−rat−HTPBTK−Consensus, RMSLE=0.43
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
3
10
factor(Route)
iv


Naphthalene−rat−In Vivo Fits, RMSLE=0.312
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
1
3
10
factor(Route)
iv


Benzophenone−rat−HTPBTK−InVitro, RMSLE=0.491
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2.5
5
10
factor(Route)
iv
oral


Benzophenone−rat−HTPBTK−ADMET, RMSLE=0.491
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2.5
5
10
factor(Route)
iv
oral


Benzophenone−rat−HTPBTK−Dawson, RMSLE=0.506
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2.5
5
10
factor(Route)
iv
oral


Benzophenone−rat−HTPBTK−Consensus, RMSLE=0.648
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2.5
5
10
factor(Route)
iv
oral


Benzophenone−rat−In Vivo Fits, RMSLE=0.323
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2.5
5
10
factor(Route)
iv
oral


2−Hydroxy−4−methoxybenzophenone−rat−HTPBTK−InVitro, RMSLE=1.45
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
8
100
250
500
factor(Route)
iv
oral


2−Hydroxy−4−methoxybenzophenone−rat−HTPBTK−ADMET, RMSLE=1.08
Concentration (mg/L)
10
1
10−1
10−2
10−3
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
8
100
250
500
factor(Route)
iv
oral


2−Hydroxy−4−methoxybenzophenone−rat−HTPBTK−Dawson, RMSLE=1.33
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
8
100
250
500
factor(Route)
iv
oral


2−Hydroxy−4−methoxybenzophenone−rat−HTPBTK−Consensus, RMSLE=1.13
Concentration (mg/L)
10
1
10−1
10−2
10−3
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
8
100
250
500
factor(Route)
iv
oral


2−Hydroxy−4−methoxybenzophenone−rat−In Vivo Fits, RMSLE=0.391
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.2
0.4
0.6
Time (Days)
factor(Dose)
8
100
250
500
factor(Route)
iv
oral


Phenolphthalein−rat−HTPBTK−InVitro, RMSLE=0.926
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
25
factor(Route)
iv


Phenolphthalein−rat−HTPBTK−ADMET, RMSLE=0.882
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
25
factor(Route)
iv


Phenolphthalein−rat−HTPBTK−Dawson, RMSLE=0.88
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
25
factor(Route)
iv


Phenolphthalein−rat−HTPBTK−Pradeep, RMSLE=0.92
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
25
factor(Route)
iv


Phenolphthalein−rat−HTPBTK−Consensus, RMSLE=0.944
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
25
factor(Route)
iv


Phenolphthalein−rat−In Vivo Fits, RMSLE=0.386
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
25
factor(Route)
iv


[4−Chloro−6−(2,3−xylidino)−2−pyrimidinylthio]acetic acid−rat−HTPBTK−InVitro, P
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
2
5
factor(Route)
iv
oral


[4−Chloro−6−(2,3−xylidino)−2−pyrimidinylthio]acetic acid−rat−HTPBTK−ADMET,
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
2
5
factor(Route)
iv
oral


[4−Chloro−6−(2,3−xylidino)−2−pyrimidinylthio]acetic acid−rat−HTPBTK−Dawson,
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
2
5
factor(Route)
iv
oral


[4−Chloro−6−(2,3−xylidino)−2−pyrimidinylthio]acetic acid−rat−HTPBTK−Pradeep
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
2
5
factor(Route)
iv
oral


[4−Chloro−6−(2,3−xylidino)−2−pyrimidinylthio]acetic acid−rat−HTPBTK−Consens
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
2
5
factor(Route)
iv
oral


[4−Chloro−6−(2,3−xylidino)−2−pyrimidinylthio]acetic acid−rat−In Vivo Fits, RMSL
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
1
2
5
factor(Route)
iv
oral


Tamoxifen−rat−HTPBTK−InVitro, RMSLE=1.58
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0.0
0.2
0.4
0.6
Time (Days)
factor(Route)
oral
factor(Dose)
0.33
0.344
0.411


Tamoxifen−rat−HTPBTK−ADMET, RMSLE=0.518
Concentration (mg/L)
10^{-2}
0.005
0.003
0.0
0.2
0.4
0.6
Time (Days)
factor(Route)
oral
factor(Dose)
0.33
0.344
0.411


Tamoxifen−rat−HTPBTK−Dawson, RMSLE=0.518
Concentration (mg/L)
10^{-2}
0.005
0.003
0.0
0.2
0.4
0.6
Time (Days)
factor(Route)
oral
factor(Dose)
0.33
0.344
0.411


Tamoxifen−rat−HTPBTK−Pradeep, RMSLE=0.518
Concentration (mg/L)
10^{-2}
0.005
0.003
0.0
0.2
0.4
0.6
Time (Days)
factor(Route)
oral
factor(Dose)
0.33
0.344
0.411


Tamoxifen−rat−HTPBTK−Consensus, RMSLE=0.518
Concentration (mg/L)
10^{-2}
0.005
0.003
0.0
0.2
0.4
0.6
Time (Days)
factor(Route)
oral
factor(Dose)
0.33
0.344
0.411


Cyclosporin A−rat−HTPBTK−ADMET, RMSLE=0.74
Concentration (mg/L)
10
3
1
0.3
0.0
0.5
1.0
Time (Days)
factor(Dose)
5.9
6
factor(Route)
iv


Cyclosporin A−rat−HTPBTK−Pradeep, RMSLE=0.558
Concentration (mg/L)
10
3
1
0.3
0.0
0.5
1.0
Time (Days)
factor(Dose)
5.9
6
factor(Route)
iv


Cyclosporin A−rat−HTPBTK−OPERA, RMSLE=0.581
Concentration (mg/L)
10
3
1
0.3
0.0
0.5
1.0
Time (Days)
factor(Dose)
5.9
6
factor(Route)
iv


Cyclosporin A−rat−HTPBTK−Consensus, RMSLE=0.766
Concentration (mg/L)
10
3
1
0.3
0.0
0.5
1.0
Time (Days)
factor(Dose)
5.9
6
factor(Route)
iv


Cyclosporin A−rat−In Vivo Fits, RMSLE=0.079
Concentration (mg/L)
10
3
1
0.3
0.0
0.5
1.0
Time (Days)
factor(Dose)
5.9
6
factor(Route)
iv


Etoxazole−rat−HTPBTK−ADMET, RMSLE=0.668
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Etoxazole−rat−HTPBTK−Dawson, RMSLE=0.707
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Etoxazole−rat−HTPBTK−Pradeep, RMSLE=0.667
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Etoxazole−rat−HTPBTK−Consensus, RMSLE=0.956
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Etoxazole−rat−In Vivo Fits, RMSLE=0.215
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
10^{-4}
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Novaluron−rat−HTPBTK−ADMET, RMSLE=1.08
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Novaluron−rat−HTPBTK−Dawson, RMSLE=1.07
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Novaluron−rat−HTPBTK−Pradeep, RMSLE=0.985
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.003
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Novaluron−rat−HTPBTK−Consensus, RMSLE=1.1
0.3
10^{-1}
0.03
10^{-2}
0.003
Concentration (mg/L)
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Novaluron−rat−In Vivo Fits, RMSLE=0.173
Concentration (mg/L)
0.3
10^{-1}
0.03
10^{-2}
0.003
0
1
2
3
Time (Days)
factor(Dose)
0.4
2
factor(Route)
iv
oral


Resmethrin−rat−HTPBTK−ADMET, RMSLE=1.04
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


Resmethrin−rat−HTPBTK−Dawson, RMSLE=0.885
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


Resmethrin−rat−HTPBTK−Pradeep, RMSLE=0.824
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


Resmethrin−rat−HTPBTK−Consensus, RMSLE=1.13
Concentration (mg/L)
10^{-1}
10^{-2}
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


Resmethrin−rat−In Vivo Fits, RMSLE=0.245
Concentration (mg/L)
0.03
10^{-2}
0.003
10^{-3}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.8
4


Pyridine−rat−HTPBTK−ADMET, RMSLE=0.95
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
0.5
2.5
5
10
25
50
100
200
factor(Route)
iv
oral


Pyridine−rat−HTPBTK−Pradeep, RMSLE=1.39
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
0.5
2.5
5
10
25
50
100
200
factor(Route)
iv
oral


Pyridine−rat−HTPBTK−OPERA, RMSLE=1.59
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
0.5
2.5
5
10
25
50
100
200
factor(Route)
iv
oral


Pyridine−rat−HTPBTK−Consensus, RMSLE=1.56
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
0.5
2.5
5
10
25
50
100
200
factor(Route)
iv
oral


Pyridine−rat−In Vivo Fits, RMSLE=0.351
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.5
1.0
1.5
Time (Days)
factor(Dose)
0.5
2.5
5
10
25
50
100
200
factor(Route)
iv
oral


2−Methylimidazole−rat−HTPBTK−ADMET, RMSLE=1.16
Concentration (mg/L)
10
1
10^{-1}
0
5
10
15
20
Time (Days)
factor(Dose)
10
factor(Route)
iv


2−Methylimidazole−rat−HTPBTK−Dawson, RMSLE=0.937
Concentration (mg/L)
10
1
10^{-1}
0
5
10
15
20
Time (Days)
factor(Dose)
10
factor(Route)
iv


2−Methylimidazole−rat−HTPBTK−Pradeep, RMSLE=1.34
Concentration (mg/L)
10
1
10^{-1}
0
5
10
15
20
Time (Days)
factor(Dose)
10
factor(Route)
iv


2−Methylimidazole−rat−HTPBTK−OPERA, RMSLE=0.988
Concentration (mg/L)
10
1
10^{-1}
0
5
10
15
20
Time (Days)
factor(Dose)
10
factor(Route)
iv


2−Methylimidazole−rat−HTPBTK−Consensus, RMSLE=1.34
Concentration (mg/L)
10
1
10^{-1}
0
5
10
15
20
Time (Days)
factor(Dose)
10
factor(Route)
iv


2−Methylimidazole−rat−In Vivo Fits, RMSLE=0.0967
Concentration (mg/L)
10
1
10^{-1}
0
5
10
15
20
Time (Days)
factor(Dose)
10
factor(Route)
iv


4−Methylimidazole−rat−HTPBTK−ADMET, RMSLE=0.392
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
factor(Route)
iv


4−Methylimidazole−rat−HTPBTK−Dawson, RMSLE=0.538
10
1
10^{-1}
Concentration (mg/L)
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
factor(Route)
iv


4−Methylimidazole−rat−HTPBTK−Pradeep, RMSLE=0.324
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
factor(Route)
iv


4−Methylimidazole−rat−HTPBTK−OPERA, RMSLE=0.5
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
factor(Route)
iv


4−Methylimidazole−rat−HTPBTK−Consensus, RMSLE=0.314
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
factor(Route)
iv


4−Methylimidazole−rat−In Vivo Fits, RMSLE=0.164
10
1
10^{-1}
Concentration (mg/L)
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
factor(Route)
iv


Dichloroacetic acid−rat−HTPBTK−ADMET, RMSLE=0.744
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
40
60
100


Dichloroacetic acid−rat−HTPBTK−Pradeep, RMSLE=0.836
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
40
60
100


Dichloroacetic acid−rat−HTPBTK−Consensus, RMSLE=0.898
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
40
60
100


Dichloroacetic acid−rat−In Vivo Fits, RMSLE=0.375
Concentration (mg/L)
30
10
3
1
0.3
0.0
0.1
0.2
0.3
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
40
60
100


Dibromoacetic acid−rat−HTPBTK−ADMET, RMSLE=0.804
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
25
40
50
100
110
125
factor(Route)
iv
oral


Dibromoacetic acid−rat−HTPBTK−Pradeep, RMSLE=0.604
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
25
40
50
100
110
125
factor(Route)
iv
oral


Dibromoacetic acid−rat−HTPBTK−Consensus, RMSLE=0.749
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
25
40
50
100
110
125
factor(Route)
iv
oral


Dibromoacetic acid−rat−In Vivo Fits, RMSLE=0.337
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
25
40
50
100
110
125
factor(Route)
iv
oral


Bromochloroacetic acid−rat−HTPBTK−ADMET, RMSLE=1.01
Concentration (mg/L)
10^2
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
40
80
100
factor(Route)
iv
oral


Bromochloroacetic acid−rat−HTPBTK−Pradeep, RMSLE=0.675
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
40
80
100
factor(Route)
iv
oral


Bromochloroacetic acid−rat−HTPBTK−Consensus, RMSLE=0.749
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
40
80
100
factor(Route)
iv
oral


Bromochloroacetic acid−rat−In Vivo Fits, RMSLE=0.386
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
10
40
80
100
factor(Route)
iv
oral


Isoeugenol−rat−HTPBTK−ADMET, RMSLE=0.738
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
17
70
140
factor(Route)
iv
oral


Isoeugenol−rat−HTPBTK−Dawson, RMSLE=0.818
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
17
70
140
factor(Route)
iv
oral


Isoeugenol−rat−HTPBTK−Pradeep, RMSLE=0.831
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
17
70
140
factor(Route)
iv
oral


Isoeugenol−rat−HTPBTK−Consensus, RMSLE=0.668
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
17
70
140
factor(Route)
iv
oral


Isoeugenol−rat−In Vivo Fits, RMSLE=0.36
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
17
70
140
factor(Route)
iv
oral


Emodin−rat−HTPBTK−ADMET, RMSLE=0.36
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
40
80
factor(Route)
iv
oral


Emodin−rat−HTPBTK−Dawson, RMSLE=0.304
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
40
80
factor(Route)
iv
oral


Emodin−rat−HTPBTK−Pradeep, RMSLE=0.328
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
40
80
factor(Route)
iv
oral


Emodin−rat−HTPBTK−OPERA, RMSLE=0.407
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
40
80
factor(Route)
iv
oral


Emodin−rat−HTPBTK−Consensus, RMSLE=0.388
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
40
80
factor(Route)
iv
oral


Emodin−rat−In Vivo Fits, RMSLE=0.189
Concentration (mg/L)
10
1
10^{-1}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
5
40
80
factor(Route)
iv
oral


Anthraquinone−rat−HTPBTK−ADMET, RMSLE=1.32
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
40
100
400
factor(Route)
iv
oral


Anthraquinone−rat−HTPBTK−Dawson, RMSLE=1.22
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
40
100
400
factor(Route)
iv
oral


Anthraquinone−rat−HTPBTK−OPERA, RMSLE=1.18
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
40
100
400
factor(Route)
iv
oral


Anthraquinone−rat−HTPBTK−Consensus, RMSLE=1.18
Concentration (mg/L)
10
1
10^{-1}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
40
100
400
factor(Route)
iv
oral


Anthraquinone−rat−In Vivo Fits, RMSLE=0.245
Concentration (mg/L)
3
1
0.3
10−1
0.03
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
40
100
400
factor(Route)
iv
oral


Oxymetholone−rat−HTPBTK−ADMET, RMSLE=0.883
Concentration (mg/L)
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
20
30
120
factor(Route)
iv
oral


Oxymetholone−rat−HTPBTK−Dawson, RMSLE=0.46
Concentration (mg/L)
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
20
30
120
factor(Route)
iv
oral


Oxymetholone−rat−HTPBTK−Pradeep, RMSLE=0.524
Concentration (mg/L)
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
20
30
120
factor(Route)
iv
oral


Oxymetholone−rat−HTPBTK−OPERA, RMSLE=0.437
Concentration (mg/L)
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
20
30
120
factor(Route)
iv
oral


Oxymetholone−rat−HTPBTK−Consensus, RMSLE=0.442
Concentration (mg/L)
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
20
30
120
factor(Route)
iv
oral


Oxymetholone−rat−In Vivo Fits, RMSLE=0.173
Concentration (mg/L)
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
20
30
120
factor(Route)
iv
oral


Formamide−rat−HTPBTK−ADMET, RMSLE=0.872
Concentration (mg/L)
10^3
10^2
10
1
0
1
2
3
4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
30
36
90
300
600


Formamide−rat−HTPBTK−Pradeep, RMSLE=1.28
Concentration (mg/L)
10^3
10^2
10
1
0
1
2
3
4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
30
36
90
300
600


Formamide−rat−HTPBTK−Consensus, RMSLE=1.28
Concentration (mg/L)
10^3
10^2
10
1
0
1
2
3
4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
30
36
90
300
600


Formamide−rat−In Vivo Fits, RMSLE=0.188
Concentration (mg/L)
10^3
10^2
10
1
0
1
2
3
4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
10
30
36
90
300
600


Primidone−rat−HTPBTK−ADMET, RMSLE=1.59
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
Time (Days)
factor(Route)
oral
factor(Dose)
30
80
130


Primidone−rat−HTPBTK−Dawson, RMSLE=1.47
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
Time (Days)
factor(Route)
oral
factor(Dose)
30
80
130


Primidone−rat−HTPBTK−Pradeep, RMSLE=1.43
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
Time (Days)
factor(Route)
oral
factor(Dose)
30
80
130


Primidone−rat−HTPBTK−OPERA, RMSLE=0.321
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
Time (Days)
factor(Route)
oral
factor(Dose)
30
80
130


Primidone−rat−HTPBTK−Consensus, RMSLE=1.61
Concentration (mg/L)
10^2
10
1
10^{-1}
0.00
0.25
0.50
0.75
Time (Days)
factor(Route)
oral
factor(Dose)
30
80
130


C.I. Solvent Red 1−rat−HTPBTK−Dawson, RMSLE=0.843
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Route)
oral
factor(Dose)
20


C.I. Solvent Red 1−rat−HTPBTK−OPERA, RMSLE=0.921
Concentration (mg/L)
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Route)
oral
factor(Dose)
20


C.I. Solvent Red 1−rat−HTPBTK−Consensus, RMSLE=0.937
1
10^{-1}
10^{-2}
10^{-3}
Concentration (mg/L)
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Route)
oral
factor(Dose)
20


Diclofenac−rat−HTPBTK−Dawson, RMSLE=0.444
Concentration (mg/L)
10^2
30
10
3
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
18
60
factor(Route)
iv
oral


Diclofenac−rat−HTPBTK−OPERA, RMSLE=0.494
Concentration (mg/L)
10^2
30
10
3
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
18
60
factor(Route)
iv
oral


Diclofenac−rat−HTPBTK−Consensus, RMSLE=0.518
Concentration (mg/L)
10^2
30
10
3
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
18
60
factor(Route)
iv
oral


Diclofenac−rat−In Vivo Fits, RMSLE=0.244
Concentration (mg/L)
10^2
30
10
3
0.0
0.1
0.2
0.3
Time (Days)
factor(Dose)
18
60
factor(Route)
iv
oral


Diltiazem−rat−HTPBTK−Dawson, RMSLE=0.593
10
1
10^{-1}
Concentration (mg/L)
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
20


Diltiazem−rat−HTPBTK−OPERA, RMSLE=0.371
10
1
10^{-1}
Concentration (mg/L)
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
20


Diltiazem−rat−HTPBTK−Consensus, RMSLE=0.371
10
1
10^{-1}
Concentration (mg/L)
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
20


Diltiazem−rat−In Vivo Fits, RMSLE=0.147
10
1
10^{-1}
Concentration (mg/L)
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Route)
iv
oral
factor(Dose)
20


Ephedrine−rat−HTPBTK−Dawson, RMSLE=0.696
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
6.25
12.5
25


Ephedrine−rat−HTPBTK−OPERA, RMSLE=0.862
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
6.25
12.5
25


Ephedrine−rat−HTPBTK−Consensus, RMSLE=0.753
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
6.25
12.5
25


Ephedrine−rat−In Vivo Fits, RMSLE=0.288
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Route)
iv
oral
factor(Dose)
6.25
12.5
25


Tetralin−rat−HTPBTK−OPERA, RMSLE=0.672
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
20
factor(Route)
iv


Tetralin−rat−HTPBTK−Consensus, RMSLE=0.672
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
20
factor(Route)
iv


Tetralin−rat−In Vivo Fits, RMSLE=0.198
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.00
0.25
0.50
0.75
1.00
Time (Days)
factor(Dose)
2
20
factor(Route)
iv


Bromodichloromethane−rat−HTPBTK−OPERA, RMSLE=0.862
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
factor(Route)
iv


Bromodichloromethane−rat−HTPBTK−Consensus, RMSLE=0.862
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
factor(Route)
iv


Bromodichloromethane−rat−In Vivo Fits, RMSLE=0.277
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
10
factor(Route)
iv


Bis(2−chloroethoxy)methane−rat−HTPBTK−OPERA, RMSLE=0.406
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
40
factor(Route)
iv


Bis(2−chloroethoxy)methane−rat−HTPBTK−Consensus, RMSLE=0.406
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
40
factor(Route)
iv


Bis(2−chloroethoxy)methane−rat−In Vivo Fits, RMSLE=0.158
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
40
factor(Route)
iv


Thiodiglycolic acid−rat−HTPBTK−OPERA, RMSLE=1.03
Concentration (mg/L)
30
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
factor(Route)
iv


Thiodiglycolic acid−rat−HTPBTK−Consensus, RMSLE=0.425
Concentration (mg/L)
30
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
factor(Route)
iv


Thiodiglycolic acid−rat−In Vivo Fits, RMSLE=0.156
Concentration (mg/L)
30
10
3
1
0.3
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
factor(Route)
iv


Oxoacetic acid−−water (1/1)−rat−HTPBTK−OPERA, RMSLE=0.703
Concentration (mg/L)
10^2
30
10
3
0.005
0.010
0.015
0.020
Time (Days)
factor(Dose)
50
factor(Route)
iv


Oxoacetic acid−−water (1/1)−rat−HTPBTK−Consensus, RMSLE=0.703
Concentration (mg/L)
10^2
30
10
3
0.005
0.010
0.015
0.020
Time (Days)
factor(Dose)
50
factor(Route)
iv


Oxoacetic acid−−water (1/1)−rat−In Vivo Fits, RMSLE=0.0763
Concentration (mg/L)
10^2
30
10
3
0.005
0.010
0.015
0.020
Time (Days)
factor(Dose)
50
factor(Route)
iv


2−Methyltetrahydrofuran−rat−HTPBTK−OPERA, RMSLE=0.76
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
2.5
10
30
40
100
400
factor(Route)
iv
oral


2−Methyltetrahydrofuran−rat−HTPBTK−Consensus, RMSLE=0.76
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
2.5
10
30
40
100
400
factor(Route)
iv
oral


2−Methyltetrahydrofuran−rat−In Vivo Fits, RMSLE=0.503
Concentration (mg/L)
10^2
10
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
2.5
10
30
40
100
400
factor(Route)
iv
oral


alpha−Thujone−rat−HTPBTK−OPERA, RMSLE=0.783
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
50
factor(Route)
oral


alpha−Thujone−rat−HTPBTK−Consensus, RMSLE=0.783
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
50
factor(Route)
oral


alpha−Thujone−rat−In Vivo Fits, RMSLE=0.35
Concentration (mg/L)
1
10^{-1}
10^{-2}
0.0
0.1
0.2
0.3
0.4
0.5
Time (Days)
factor(Dose)
25
50
factor(Route)
oral


1−Chloro−2−propanol−rat−HTPBTK−OPERA, RMSLE=0.892
Concentration (mg/L)
3
1
0.3
10^{-1}
0.000
0.025
0.050
0.075
0.100
0.125
Time (Days)
factor(Route)
oral
factor(Dose)
1.5
7.5
15


1−Chloro−2−propanol−rat−HTPBTK−Consensus, RMSLE=0.413
Concentration (mg/L)
3
1
0.3
10−1
0.000
0.025
0.050
0.075
0.100
0.125
Time (Days)
factor(Route)
oral
factor(Dose)
1.5
7.5
15


3,3',4,4',5−Pentachlorobiphenyl−rat−HTPBTK−OPERA, RMSLE=0.741
Concentration (mg/L)
3e−04
10−4
3e−05
10−5
0
100
200
300
Time (Days)
factor(Dose)
1e−05
0.001
factor(Route)
oral


3,3',4,4',5−Pentachlorobiphenyl−rat−HTPBTK−Consensus, RMSLE=0.939
Concentration (mg/L)
3e−04
10−4
3e−05
10−5
0
100
200
300
Time (Days)
factor(Dose)
1e−05
0.001
factor(Route)
oral


Perfluorooctanesulfonate−rat−HTPBTK−Consensus, RMSLE=0.618
Concentration (mg/L)
10^2
10
1
10^{-1}
0
50
100
Time (Days)
factor(Route)
iv
oral
factor(Dose)
2
20


Perfluorooctanesulfonate−rat−In Vivo Fits, RMSLE=0.254
Concentration (mg/L)
10^2
10
1
10^{-1}
0
50
100
Time (Days)
factor(Route)
iv
oral
factor(Dose)
2
20


2−(Perfluorooctyl)ethanol−rat−In Vivo Fits, RMSLE=0.405
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0.0
0.5
1.0
1.5
2.0
Time (Days)
factor(Dose)
12
24
40
48
80
160
factor(Route)
iv
oral


Carbon disulfide−rat−In Vivo Fits, RMSLE=0.139
Concentration (mg/L)
10
3
1
0.00
0.02
0.04
0.06
0.08
Time (Days)
factor(Dose)
10
50
factor(Route)
iv


Hexachlorobenzene−rat−In Vivo Fits, RMSLE=0.176
Concentration (mg/L)
10
1
10^{-1}
10^{-2}
10^{-3}
0
20
40
60
80
Time (Days)
factor(Route)
iv
oral
factor(Dose)
0.03
0.1
0.3
1
30


Nitrite ion−rat−In Vivo Fits, RMSLE=0.253
Concentration (mg/L)
30
10
3
1
0.0
0.1
0.2
0.3
0.4
Time (Days)
factor(Dose)
20
40
80
factor(Route)
iv
oral